Evolving Market Trends In The Intravenous Immunoglobulin Industry: GC Pharma Launches Innovative Liquid Immune Globulin Formulation For Immunodeficiency Treatment

The Intravenous Immunoglobulin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Intravenous Immunoglobulin Market Size During the Forecast Period?
In recent years, the intravenous immunoglobulin market has experienced significant expansion. Its growth is projected to increase from $14.66 billion in 2024 to $15.72 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. This historic growth can be credited to factors such as the treatment of primary immunodeficiency diseases, the management of neurological disorders, an increasing elderly population, advances in plasma fractionation methods, extended applications in neurology, and the treatment of infectious diseases and pediatric immunodeficiency.

The size of the intravenous immunoglobulin market is predicted to experience significant expansion in the upcoming years, with projections indicating a growth to $22.01 billion by 2029 at a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this anticipated growth during the forecast period include the rising incidence of autoimmune disorders, ongoing immunology research, increased healthcare spending, a rise in cancer cases, advancements in immunoglobulin products, and the utilization of personalized medicine tactics. Key trends expected during this future period encompass treatment of primary immunodeficiency disorders (PIDD), rapid technological evolution, strategic alliances and collaborations, advancements in manufacturing methods, neurology indications, hematology application, and progression in immunotherapy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8538

What Are the High-Growth Segments in the Intravenous Immunoglobulin Market?
The intravenous immunoglobulin market covered in this report is segmented -

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care

Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Key Drivers Are Expected to Influence Future Intravenous Immunoglobulin Market Growth?
The rise in the elderly population is anticipated to propel the growth of the intravenous immunoglobulin market. The term elderly population refers to individuals who are aged 65 years and above. As people age, their immunity systems diminish, reducing the production of antibodies. Consequently, they require immunoglobulins to supplement these antibodies. This results in a boost in demand for intravenous immunoglobulins and propels the intravenous immunoglobulin market. For instance, the Population Reference Bureau, a nonprofit organization based in Kenya, projected in January 2024 that the number of Americans aged 65 and above will increase from 58 million in 2022 to 82 million by 2050, showcasing a 47% rise. The percentage of this age group in the total population is also expected to increase from 17% to 23% within the same timeframe. Therefore, the growth of the elderly population is set to accelerate the growth of the intravenous immunoglobulin market.

Which Companies Hold the Largest Share Across Different Intravenous Immunoglobulin Market Segments?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

What Trends Are Driving Growth in The Intravenous Immunoglobulin Market?
In the world of intravenous immunoglobulin market, product innovation is a significant trend that is gaining traction. Major firms in this sector are making strides in new product advancement, focusing on creations such as liquid immune globulin formulations that can treat immunodeficiency diseases. Their aim is to solidify their market standing. An example of this is seen when GC Pharma, a pharmaceutical company based in South Korea, in December 2023, unveiled Alyglo, a product with the approval of the US Food and Drug Administration (FDA). Alyglo, a sterile, ready-to-use liquid formulation, contains 10% immunoglobulin G (IgG), offering 100 mg/mL of protein where at least 96% is human IgG extracted from pooled human plasma. The drug is specifically designed for adults 17 years and older living with primary humoral immunodeficiency (PI). It addresses conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

What Are the Emerging Geographies for The Intravenous Immunoglobulin Market Growth?
North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Intravenous Immunoglobulin Market?
2. What is the CAGR expected in the Intravenous Immunoglobulin Market?
3. What Are the Key Innovations Transforming the Intravenous Immunoglobulin Industry?
4. Which Region Is Leading the Intravenous Immunoglobulin Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.